The design of this registered study aims to evaluate the efficacy and safety of Paxlovidin the treatment of hospitalized COVID-19 patients, and to explore factors related to theefficacy and safety of Paxlovid.
Not Provided
Drug: paxlovid
Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be
included in this group. Patients treated with PAXLOVID will be included in this group.
This study is a non-interventional observational study, and no intervention measures were
applied to the clinical diagnosis and treatment process of hospitalized COVID-19
patients. The use of Paxlovid is completely decided by the clinical doctors based on the
patients' condition and clinical experience.
Other Name: paxlovid within initial 5 days
Drug: No paxlovid
Patients not treated with PAXLOVID will be included in this group. This study is a
non-interventional observational study, and no intervention measures were applied to the
clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of
Paxlovid is completely decided by the clinical doctors based on the patients' condition
and clinical experience.
Drug: Paxlovid
Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with
covid-19 will be included in this group.
Other Name: Paxlovid outside of the initial 5 days
Inclusion Criteria:
1. Confirmed diagnosis of COVID-19 infection.
2. Presence of at least one high-risk factor, including age ≥60 years, diabetes,
hypertension, cardiovascular disease, stroke, chronic liver or kidney disease,
cancer, history of smoking or obesity.
Exclusion Criteria:
- No specific exclusion criteria in this study.
Not Provided
Yi Zhang, PhD
+86 01085231464
jeffzhang1619@outlook.com